CoChat

A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias

Lionetti, Marta, Barbieri, Marzia, Todoerti, Katia, Agnelli, Luca, Fabris, Sonia, Tonon, Giovanni, Segalla, Simona, Cifola, Ingrid, Pinatel, Eva, Tassone, Pierfrancesco, Musto, Pellegrino, Baldini, Luca, Neri, Antonino · 2015 · Oncotarget
Cited by 49

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.4674

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 33

  1. Fonseca, 2011, Plasma cell leukemia, Blood Rev, 25, 107, 10.1016/j.blre.2011.01.005 · DOI
  2. Auclair, 2011, Initial genome sequencing and analysis of multiple myeloma, Nature, 471, 467, 10.1038/nature09837 · DOI · Paper page
  3. Carpten, 2012, Clonal competition with alternating dominance in multiple myeloma, Blood, 120, 1067, 10.1182/blood-2012-01-405985 · DOI · Paper page
  4. Morgan, 2012, Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma, Blood, 120, 1077, 10.1182/blood-2012-03-412981 · DOI · Paper page
  5. Tonon, 2015, Molecular spectrum of BRAF, NRAS, and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation, Oncotarget, 6, 24205, 10.18632/oncotarget.4434 · DOI
  6. Dziembowski, 2011, The eukaryotic RNA exosome: same scaffold but variable catalytic subunits, RNA Biol, 8, 61, 10.4161/rna.8.1.14237 · DOI · Paper page
  7. Dziembowski, 2014, Multiple myeloma-associated hDIS3 mutations cause perturbations in cellular RNA metabolism and suggest hDIS3 PIN domain as a potential drug target, Nucleic Acids Res, 42, 1270, 10.1093/nar/gkt930 · DOI · Paper page
  8. Carvalho, 2014, Gene-dosage dependent overexpression at the 13q amplicon identifies DIS3 as candidate oncogene in colorectal cancer progression Genes Chromosomes, Cancer, 53, 339
  9. Van Gorp, 2013, A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer—a study of the OVCAD consortium, BMC Cancer, 13, 178, 10.1186/1471-2407-13-178 · doi:10.1186/1471-2407-13-178
  10. Leich, 2015, The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma, Br J Haematol, 169, 57, 10.1111/bjh.13256 · DOI · Paper page
  11. Tonon, 2015, The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA, Nucleic Acids Res, 43, 5182, 10.1093/nar/gkv387 · DOI · Paper page
  12. Conti, 2008, Structure of the active subunit of the yeast exosome core, Rrp44: diverse modes of substrate recruitment in the RNase II nuclease family, Mol Cell, 29, 717, 10.1016/j.molcel.2008.02.018 · DOI · Paper page
  13. Neri, 2009, A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect, Genes Chromosomes Cancer, 48, 603, 10.1002/gcc.20668 · DOI · Paper page
  14. D'Auria, 2013, Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles, Am J Hematol, 88, 16, 10.1002/ajh.23339 · DOI · Paper page
  15. Seraphin, 2007, A single subunit, Dis3, is essentially responsible for yeast exosome core activity, Nat Struct Mol Biol, 14, 15, 10.1038/nsmb1184 · DOI · Paper page
  16. Bargou, 2013, Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules, Blood Cancer Journal, 3, e102, 10.1038/bcj.2012.47 · DOI
  17. Raimondo, 2015, Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns, Oncotarget, 6, 17543, 10.18632/oncotarget.4028 · DOI
  18. Grossniklaus, 2007, Genome-wide high-resolution mapping of exosome substrates reveals hidden features in the Arabidopsis transcriptome, Cell, 131, 1340, 10.1016/j.cell.2007.10.056 · DOI · Paper page
  19. Tollervey, 2006, Microarray detection of novel nuclear RNA substrates for the exosome, Yeast, 23, 439, 10.1002/yea.1369 · DOI
  20. Andrulis, 2010, Genome-wide analysis reveals distinct substrate specificities of Rrp6, Dis3, and core exosome subunits, RNA, 16, 781, 10.1261/rna.1906710 · DOI · Paper page
  21. Stetson, 2014, The SKIV2L RNA exosome limits activation of the RIG-I-like receptors, Nat Immunol, 15, 839, 10.1038/ni.2948 · DOI · Paper page
  22. Futreal, 2014, Differential and limited expression of mutant alleles in multiple myeloma, Blood, 124, 3110, 10.1182/blood-2014-04-569327 · DOI
  23. Guariglia, 2014, Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia, Leukemia, 28, 222, 10.1038/leu.2013.241 · DOI
  24. International Myeloma Working G, 2003, Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group, Br J Haematol, 121, 749, 10.1046/j.1365-2141.2003.04355.x · DOI · Paper page
  25. Salmon, 1975, A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival, Cancer, 36, 842, 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U · DOI · Paper page
  26. Neri, 2007, Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma, Br J Haematol, 136, 565, 10.1111/j.1365-2141.2006.06467.x · DOI
  27. De Luca, 2013, Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome, Clin Cancer Res, 19, 3247, 10.1158/1078-0432.CCR-12-3461 · DOI
  28. Neri, 2007, Molecular characterization of human multiple myeloma cell lines by integrative genomics: Insights into the biology of the disease, Genes Chromosomes & Cancer, 46, 226, 10.1002/gcc.20404 · DOI · Paper page
  29. Chiaramonte, 2014, Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line, Genes Chromosomes Cancer, 53, 154, 10.1002/gcc.22127 · DOI
  30. Neri, 2005, Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses, Genes Chromosomes Cancer, 42, 117, 10.1002/gcc.20123 · DOI
  31. Stelitano, 2005, Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma, Oncogene, 24, 2461, 10.1038/sj.onc.1208447 · DOI
  32. Ilariucci, 2014, High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications, Br J Haematol, 165, 629, 10.1111/bjh.12800 · DOI
  33. Chu, 2001, Significance analysis of microarrays applied to the ionizing radiation response, Proc Natl Acad Sci U S A, 98, 5116, 10.1073/pnas.091062498 · DOI · Paper page

Cited by

See all 49

Metadata

Authors
Lionetti, M., Barbieri, M., Todoerti, K., Agnelli, L., Fabris, S., Tonon, G., Segalla, S., Cifola, I., Pinatel, E., Tassone, P., Musto, P., Baldini, L., & Neri, A.
Venue
Oncotarget
Published
2015-07-20
Volume
6
Issue
28
Pages
26129-26141
ISSN
1949-2553
Cited by
49
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.